Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 776 - Advisory Council for the Elimination of Tuberculosis - Statutory (Congress Created)
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameAdvisory Council for the Elimination of TuberculosisAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number776
Original Establishment Date8/15/1990Committee StatusChartered
Actual Termination Date Committee URLhttps://www.cdc.gov/faca/committees/acet.html
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*48
Current Charter Date3/15/2019Designated Fed Officer Position Title*Acting DFO
Date Of Renewal Charter3/15/2021Designated Federal Officer PrefixDr.
Projected Termination Date Designated Federal Officer First Name*Carla
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Winston
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPh.D., M.A.
Specific Establishment Authority*Section 3I7E(f) of the PHS Act, [42 U.S.C. §247b-6(f)], as amended; (Section 2(b)), Public Law 101-368Designated Federal Officer Phone*(404) 639-8120
Effective Date Of Authority*8/15/1990Designated Federal Officer Fax*(404) 718-8308
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*ctw3@cdc.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Advisory Council for the Elimination of Tuberculosis (ACET) accomplishes its purpose by reviewing Department of Health and Human Service (HHS) policies, plans and procedures; advising on emerging problems in tuberculosis (TB) control; developing guidelines and recommendations related to TB elimination; and by forming temporary workgroups to address specific TB elimination issues.
How is membership balanced?*The Council’s membership is composed of experienced, credible, and recognized experts with diverse points of view in the fields of TB diagnosis, treatment, prevention, and control, public health, infectious diseases, epidemiology, pulmonary disease, pediatrics, and microbiology. The recruitment process ensures that the membership is fairly balanced by geographic region, race/ethnicity, gender, expertise and perspective. The diversity offered by the varied expertise and experience of this council’s membership is necessary to succeed in the elimination of TB.
How frequent & relevant are cmte mtgs?*The Council meets two times annually on issues relevant to elimination of tuberculosis as outlined in the Council’s charter. Meeting outcomes may include providing recommendations and guidance to CDC regarding policies, strategies, objectives, and priorities; and addressing the development and application of new technologies.

ACET provided advice and recommendations on a number of critical issues which included the publication of the Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers – guidance to provide an introduction and reference tool for tuberculosis (TB) controllers regarding the essential components of a public health program to prevent, control, and eliminate TB.

In December 2019, ACET submitted correspondence to the HHS Secretary regarding six concerns that continue to be paramount during ACET deliberations which included the following: 1) strengthening the TB public health infrastructure; 2) intermittent shortages of anti-TB drugs; 3) targeted testing of individuals at risk for progression from latent tuberculosis infection to active TB disease; 4) TB in congregate settings with particular emphasis on correctional institutions and homeless settings; 5) TB research; and 6) TB among persons along the U.S.-Mexico border.

The ACET Latent Tuberculosis Infection (LTBI) Workgroup provided updates on the workgroup’s activities and progress. During the December 2019 ACET meeting, the LTBI Workgroup provided an update on the draft report and approved “A roadmap to TB elimination: focus on LTBI” report for possible publication in the Morbidity and Mortality Weekly Report (MMWR). This report outlines four major recommendations for scaling up LTBI testing and treatment in the United States, namely: (1) identify and engage individuals at-risk and their providers; (2) increase testing of at-risk individuals and increase treatment of infected individuals; (3) measure success and outcomes of LTBI testing and treatment scale-up; and (4) secure funding for these activities. There are numerous activities under each of these strategies.

In June 2020, ACET submitted correspondence to the HHS Secretary requesting that the recommendations in the “Roadmap for Advancing TB elimination in the United States through Scale up of Testing and Treatment of Latent TB Infection” report be accepted and that the document be submitted to the MMWR and other appropriate journals for publication. This report provides a major update to the 1989 Strategic Plan for the elimination of tuberculosis in the United States publication. In the past two decades, the epidemiology of TB in the U.S. has changed. To date, strategies to control TB in the United States have focused rapidly on finding and treating patients with active TB disease and testing and treating with minimal focus on the larger reservoir of persons with latent TB infection.

In 2019, the ACET Drug Supply Workgroup continued to engage in a number of meetings to review ongoing challenges primarily centered on single manufacturers, cost escalations, and difficulties with the continuing clofazimine non-tuberculous mycobacterium process. An update was provided at the December 2019 meeting. ACET will invite the appropriate person from the Food and Drug Administration to discuss and address the issues related to drug supply at the December 8-9, 2020 ACET meeting.

In July 2020, the Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers was published in the Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports. The report re-emphasizes the importance of well-established priority strategies for TB prevention and control: identification of and completion of treatment for persons with active TB disease; finding and screening persons who have had contact with TB patients; and screening, testing, and treatment of other selected persons and populations at high risk for latent TB infection (LTBI) and subsequent active TB disease.
Why advice can't be obtained elsewhere?*Although tuberculosis (TB) is both preventable and curable, this life-threatening disease remains a serious problem in the United States. TB disease and latent TB infection (LTBI) are present in every state; in rural areas as well as cities; in schools, workplaces, and homes; and in places where persons spend time in close contact with others (e.g., correctional facilities and homeless shelters). Innovative and expanded approaches are required for eliminating TB in the United States, especially as concerns increase regarding antimicrobial resistance. CDC has proposed multiple interventions for accelerating the decrease in US TB incidence, including increasing LTBI testing and treatment among populations at high risk, enhancing detection of TB cases to reduce transmission by providing treatment as prevention, and improving TB treatment regimens to increase the proportion of TB patients successfully completing treatment. The Advisory Council for the Elimination of Tuberculosis is the only Federal advisory committee chartered to address US TB elimination; it is continually active, and its advice, recommendations, and guidance are crucial as CDC and its public health partners develop, implement, and evaluate innovative and expanded approaches to TB elimination.

The Council will continue to provide guidance or advice on TB: 1) elimination strategies; 2) laboratory testing and drug resistance; 3) new diagnostics and drugs to fight TB; 4) management and care; 5) in correctional settings; 6) issues on the US/Mexico border; 7) outbreaks occurring in special populations, particularly the homeless; 8) drug and diagnostic shortages; and 9) implementation of expanded LTBI testing and treatment as recommended by U.S. Preventive Services Task Force (USPSTF).
Why close or partially close meetings?N/A
Recommendation Remarks
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentThe agency works closely with the Chair of the Advisory Council to identify priorities and issues to be addressed at Advisory Council meetings. Prior to the meetings, the agency works with ACET to prepare agendas and provides background materials to Advisory Council members. The agency also provides support to ACET workgroups and as needed, to external experts to focus on priority issues under the authority of the Advisory Council.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentN/ANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThere was no apparent cost-savings in comparison to the previous year by having one face-to-face meeting in Atlanta and one Web-Based meeting in Fiscal Year 2020.Grants Review CommentACET does not perform grant reviews.
Number Of Recommendations*168Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe recommendations fall under these categories: ACET Drug Supply Workgroup updates, ACET Latent Tuberculosis Infection (LTBI) Workgroup updates on the report: A roadmap to TB elimination: focus on LTBI, for possible publication in the Morbidity and Mortality Weekly Report (MMWR), and the publication of the Essential Components of a Public Health Tuberculosis, Prevention, Control, and Elimination Program in the MMWR Recommendations and Reports.Access Agency WebsiteYes
% of Recs Fully Implemented*77.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentNarrative: For the life of this committee, 146 recommendations were either fully or partially implemented. Some recommendations have not been implemented by the agency.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*23.00%Access PublicationsYes
% of Recs Partially Implemented CommentWe are working with the programs on a routine basis to update partially implemented recommendations.Access OtherNo
Agency Feedback*YesAccess Commenthttps://www.cdc.gov/maso/facm/facmacet.html
Agency Feedback Comment*Feedback is provided through several venues to the ACET at Committee meetings: by written and electronic correspondence; and in reports and recommendations, which are published in CDC’s Morbidity and Mortality Weekly Reports.Narrative Description*The Council supports the agency’s mission by bringing tuberculosis (TB) issues to national attention, particularly those having an impact on national health outcomes and/ or goals. The Council reviews and evaluates CDC activities, guidelines and other national policies that impacts TB control; provides input and recommendations; and monitors TB control and elimination efforts. The Council also forms issue-specific workgroups, provides direct feedback to HHS and CDC during meetings, and communicates with the Secretary, Department of Health and Human Services (HHS).
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$5,500.00Est Payments to Non-Fed Members Next FY*$10,000.00
Payments to Federal Members*$20,960.00Est. Payments to Fed Members Next FY*$15,720.00
Payments to Federal Staff*$113,855.00Estimated Payments to Federal Staff*$108,876.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$9,839.00Est Travel Reimb Non-Fed Members nextFY*$14,109.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$1,342.00Est Travel Reimb to Consultants Next FY*$3,471.00
Other Costs$4,426.00Est. Other Costs Next FY*$4,470.00
Total Costs$155,922.00Est. Total Next FY*$156,646.00
Federal Staff Support (FTE)*0.87Est. Fed Staff Support Next FY*0.92
Cost RemarksCosts difference reflects a decrease in the number of in-person meetings held, and lower administrative and staff costs.Est Cost RemarksPayments to federal staff decreased in FY21 due to support staff changes. Also, the number of ex officio members will decrease in the 2021 charter renewal resulting in a decrease in projected payments to Federal members.
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Treatment
Medicine
Diseases
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036504Advisory Council for the Elimination of Tuberculosis2019
 COM-034709Advisory Council for the Elimination of Tuberculosis2018
 COM-001983Advisory Council for the Elimination of Tuberculosis2017
 COM-002334Advisory Council for the Elimination of Tuberculosis2016
 COM-004131Advisory Council for the Elimination of Tuberculosis2015
 COM-004469Advisory Council for the Elimination of Tuberculosis2014
 COM-006251Advisory Council for the Elimination of Tuberculosis2013
 COM-006949Advisory Council for the Elimination of Tuberculosis2012
 COM-007964Advisory Council for the Elimination of Tuberculosis2011
 COM-008688Advisory Council for the Elimination of Tuberculosis2010
 COM-010291Advisory Council for the Elimination of Tuberculosis2009
 COM-011045Advisory Council for the Elimination of Tuberculosis2008
 COM-011921Advisory Council for the Elimination of Tuberculosis2007
 COM-012541Advisory Council for the Elimination of Tuberculosis2006
 COM-014121Advisory Council for the Elimination of Tuberculosis2005
 COM-014748Advisory Council for the Elimination of Tuberculosis2004
 COM-015668Advisory Council for the Elimination of Tuberculosis2003
 COM-016783Advisory Council for the Elimination of Tuberculosis2002
 COM-017909Advisory Council for the Elimination of Tuberculosis2001
 COM-018771Advisory Council for the Elimination of Tuberculosis2000
 COM-019828Advisory Council for the Elimination of Tuberculosis1999
 COM-020626Advisory Council for the Elimination of Tuberculosis1998
 COM-021581Advisory Council for the Elimination of Tuberculosis1997